Biotech Stocks: The Ultimate Investment?


The Biotech stocks in our Billionaires Portfolio have returned an annualized 129%. One of our biotech stocks up almost 270% and another biotech stock up more than 70% in less than 2 months.

These stocks have the ability to produce multiple returns, but they have little if any correlation to the overall stock market. Last week, the stock market had its worst one day performance since November. Yet, the biotech stocks in our portfolio gained on average 6% versus a negative 1.5% for the S&P 500.

In 2008 when the S&P 500 lost 37%, the small cap biotech sector actually gained a positive 9%. In 2011 when almost every fund lost money and the market was up a meager 3%, the biotech sector was up 10%. I have two top billion dollar biotech hedge funds in my database that have produced an average annualized return of 45% a year since 2002, without one losing year.

I honestly know of no other investment vehicle that can claim those results. Why? Because biotech stocks are the ultimate event-driven investment. It’s all about FDA approvals, results from clinical data and news of partnerships. That’s the driver and it can unlock value in a rising or falling stock market — it doesn’t matter.

The secret to investing in biotech stocks: follow the smart money. That is to only invest in the biotech stocks. You want the stocks owned by the world’s best billionaire biotech investors and hedge funds.

Will Meade
President of The Billionaires Portfolio
Providing Sophisticated Hedge Fund Strategies and Analysis For The Everyday Investor